David DeGraff
@DavidDeGraff5
Followers
717
Following
5K
Media
46
Statuses
2K
Cancer biologist and recovering PI. Views are my own. RT does not equal endorsements.
Hershey, PA
Joined August 2018
Deep thoughts on leaving academics… The amount of silly and redundant emails I receive has dramatically decreased since leaving academics. This is nice.
9
4
145
Terrific panel #UromigosLive @tompowles1 asking Qs on adjuavnt Tx in RCC A rich conversation with differing views. @Uromigos @TresUramigas @uromigosjapan @DrChoueiri @HHammersMD @crisuarez08 @montypal
0
9
26
Assessing baseline bladder function for patients considering trimodal therapy. Comron Hassanzadeh, MD, MPH joins @UroDocAsh to discuss emerging comprehensive bladder toxicity measurement tools. The discussion covers technical advances, including IMRT optimization to reduce
0
2
5
Meet the Greek: A New Podcast on Cancer Care & Research https://t.co/yiFP5H68kK via @YouTube Am so excited about it,looking forward to thoughts; audience is broad! 1st episode link below, more coming! @fredhutch @montypal @neerajaiims @UroDocAsh @HsiehLab @spsutkaMD @OncoAlert
6
20
58
🚀 Fantastic to see @PGrivasMDPhD launch the new Oncology Insights podcast with @fredhutch👉sharp clinical expertise & a global perspective on cancer care, trials, and education. Episode 1 is a must-watch — insightful & deeply engaging. @ASCO @BladderCancerUS @FredHutchGO
Meet the Greek: A New Podcast on Cancer Care & Research https://t.co/yiFP5H68kK via @YouTube Am so excited about it,looking forward to thoughts; audience is broad! 1st episode link below, more coming! @fredhutch @montypal @neerajaiims @UroDocAsh @HsiehLab @spsutkaMD @OncoAlert
1
12
22
No Shave November ’25 is LIVE! Join Penn State Health Urology & @MidPennBank as we kick off year 10! Every beard grown, every dollar given, every patient helped, that’s what is all about. Stay tuned for updates all month long! Donate ➡️ https://t.co/Olgamt0z3l
0
3
11
📢 Excited to share the latest from our lab: we discovered a new synthetic-lethal vulnerability in cancer cells with APOBEC3A activity and its underlying mechanism 🔧🧩 -APOBEC3A induces DNA double-strand breaks🧬✂️🧬 - APOBEC3A shifts double-strand DNA break repair towards
10
47
160
Welcome, Dr. Khurshid Ghani! We are excited to have you as our Fall Visiting Professor!
0
2
14
Great start to the series with Dr. Ghani’s insightful talk on surgical lasers! Incredibly informative and engaging! Can’t wait for the next two sessions! #urology #MensHealth
0
3
14
Phenomenal discussion from @shilpaonc @ClevelandClinic in the #bladdercancer mini-oral session. Beautiful summary from data spanning #HRQOL w #perioperative #durvalumab, #FGFR3 & #TROP2 targeting & novel combinations. #ESMO25
3
10
18
Finally, we have large RCTs to debate, discuss, and comb over and not just single arm trials. The amount we will learn about NMIBC from these cohorts will be vast.
ALBAN, POTOMAC & CREST #ESMO25 (atezolizumab/sasalimab/in MIBC) @Annals_Oncology show a lot variability. It no easy to conclude exactly which NMIBC patients benefit from ICI therapy. There is over treatment and it’s not without toxicity @JoshMeeks
0
4
10
Interesting data on POL Theta inhibitors in human cancers @artiospharma #ESMO25
First human data for a DNA pol theta inhibitor? Artios's ART6043 +/-Lynparza in solid tumours shows 1 cPR + 1 uCR... via Tim Yap #ESMO25
0
1
4
Important study - and a timely reminder that BCG continues to perform remarkably well. Negative trials like this are valuable; they help define where systemic therapy may (or may not) add to an already effective backbone. #ESMO25 @IBCG_BladderCA @UroToday @MRoupret @y_loriot
At @myESMO #esmo2025 Berlin, I had the privilege to present the #ALBAN trial (GETUG–AFU 37), an academic phase III study led by @AFUrologie & @GETUG_Unicancer @LaCarine1 together with my outstanding co-PI @y_loriot ,co-investigators @PignotG @champiatMD @PrRomainMATHIEU
1
8
40
Our friends at @UroToday have published a series of video interviews with leading urologists, oncologists other HCPs and researchers based upon fascinating sessions at #BCANTT25. We invite you to click and peruse their collection: https://t.co/fDGWsBhAjq
2
4
10
⚡️ Cost-effectiveness of treatments for BCG-unresponsive CIS - analysis from our multicenter IBCG team. Five strategies modeled: 🔹Radical cystectomy (RC) 🔹Pembrolizumab 🔹Nadofaragene firadenovec 🔹Nogapendekin (NAI-BCG) 🔹Gemcitabine + Docetaxel ➡️Comprehensive
4
43
117
Kudos to @joeclarkmd, along with Lizzie Welsh, a former AI with us, and Joseph Park, a former radiology resident at Penn State Health, on their recent publication “Equivocal Penile Fracture Clarified by MRI.” Congratulations on this excellent work! Link: https://t.co/PHnKIXExys
0
2
5
Just in @JCOPO_ASCO! Our work on FGFR 3 Alteration Status and Outcomes on ICIs in pts with mUC We performed a large real world study (N=1416) 🧵 Key findings 👇 https://t.co/HNFWFGyydY
ascopubs.org
PURPOSEThe use of immune checkpoint inhibitors (ICPIs) has expanded in the treatment of metastatic urothelial carcinoma (mUC), but response rates are variable, highlighting the need for predictive...
4
12
40
Important grant opportunity for bladder cancer research from @BladderCancerUS!
🚨 Brand-new funding opportunity from BCAN! The Patient-Centered Clinical Research Award supports investigators ready to expand their careers in patient-focused bladder cancer research. Applications now open: https://t.co/thgPAyBG0D. Image generated by AI.
0
4
4
#GUONCCLE25 @PBarataMD #Prostatecancer session with an amazing multi-D panel across @UHhospitals @CleClinicMD
@ChrisWeeMD @angela_jia_ #PrateekMendiratta #ZurabDavili Great interactive discussions in an era of rapidly changing landscape @UHhospitals @CleClinicMD
@PCFnews
3
6
40